Asset Manager

Updated:

BioInfleXion Point Partners

BioInfleXion Point Partners invests in bio-convergence — growth-stage digital health, biotech, and therapeutics — from Ann Arbor and San Francisco.

BioInfleXion Point Partners

BioInfleXion Point Partners is a venture investment firm focused on early-stage biotechnology and life sciences companies. Founded in 2013, it is based in San Francisco, California. The firm has made one investment, in Akadeum Life Sciences, as part of their Seed VC - III on August 31, 2017.

General information

Firm type

Asset Manager

Year founded

AUM

Undisclosed

Location

Region

North America

Country

United States

City

Ann Arbor

Corporate office

Ann Arbor, Michigan, San Francisco, United States

Sector focus

Digital HealthBiotechPharma ServicesHealthcare Services

Frequently asked questions

What types of companies does BioInfleXion Point Partners typically invest in?

The firm targets growth-stage companies at the intersection of biology and technology, including digital health platforms, biotech tools, diagnostics, and therapeutics. It focuses on areas like precision medicine, drug-discovery AI, and real-world evidence analytics. Deal stage is likely Series B and beyond, based on typical growth-equity mandates (per public record).

Where is BioInfleXion Point Partners located?

The firm operates from two US hubs: Ann Arbor, Michigan, and San Francisco, California. This dual-location setup suggests a strategy of accessing both Midwest research institutions and West Coast commercial and venture ecosystems. No other offices are publicly disclosed.

Who are the key investment professionals at BioInfleXion Point Partners?

The names and roles of the firm's leadership are not publicly available. Based on the firm's focus, its team likely includes individuals with backgrounds in venture capital, pharmaceutical R&D, and academic health centers. Without a disclosed team page, verification is not possible.

Does BioInfleXion Point Partners disclose its assets under management?

No. The firm does not publicly report AUM or committed capital. There are no filings or press releases indicating fund size, deployment, or institutional backers. The AUM is classified as undisclosed by public sources.

Is BioInfleXion Point Partners a single family office or an independent asset manager?

The firm's exact legal structure is not publicly known. No evidence links it to a specific family or endowment. It likely operates as an independent growth-equity manager, but categorization remains uncertain without official confirmation.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on asset managers?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More Ann Arbor Asset Manager profiles